about
Acyl chain orientational order in the hexagonal HII phase of phospholipid-water dispersions.Molecular biomarker analyses using circulating tumor cellsDiurnal variation of the human adipose transcriptome and the link to metabolic disease.Development of a microarray platform for FFPET profiling: application to the classification of human tumors.A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.Oxidation of gamma II-crystallin solutions yields dimers with a high phase separation temperatureImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.Comparison of the orientational order of lipid chains in the L alpha and HII phasesDynamic critical phenomena in aqueous protein solutionsDistinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemiaSingle cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo propertiesImaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyPharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsTime-to-Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine-Citrulline-Monomethylauristatin E Antibody-Drug Conjugates89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
P50
Q28361247-624284F1-2EA3-45A5-9F75-E6FF285BCA16Q28749394-BCCAAA5B-525F-4462-B9CC-3FEC663E830CQ33407039-2CD72A13-EA2C-4C6B-B0B9-F747CCEC296EQ33488115-566742FC-410C-4F55-AB74-D2E6E9A2DFA2Q34557719-2A095963-3D4A-435B-AF5C-81E9A366FEC6Q34682416-0D4A088D-06F0-43E9-A929-CCC568623FD5Q38383429-4E9AC1C9-3A08-4913-9D60-05D6466990AFQ38411699-49E8A36A-DBBC-47D7-B3FE-86F06B7E9861Q38988952-89E7D5E3-7D85-459D-B4E8-BF12B5792845Q40467181-E84211AC-3162-4FDE-BA73-8947DF820EA4Q41960520-36B22F6C-B3D0-4237-9B23-90A359F13D62Q46066416-685D62C3-CDC5-49F4-A80E-3C6AF6F5B8CEQ46504066-4285AD42-9312-4594-97BB-A8F457352182Q47973033-2AE0B32E-3893-4DEA-BEF2-37274FAF6699Q53161184-7C0FD57E-0A95-4C59-A9C7-C10925C15009Q68622982-3514C46F-6382-4C0A-BFD1-B52DD3464F36Q74555289-B5ADF213-9CFC-4553-BA4F-71191E84A284Q80607032-607C81A5-6E5F-476B-8DC2-CAE463F5F7B4Q90496208-221F49D2-61D9-4C8E-A74E-6D55F3E6C62DQ91751299-7DFE9A9C-CD95-4C53-B7C0-0228F00E206BQ92220934-4F384153-970F-4403-9B99-8EC9BC679CFCQ92809136-0D1CB602-8593-4A77-9ED2-B911A32A1A7BQ93382061-3403429B-6C8D-4E9F-86E9-150483819B71
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bernard M Fine
@ast
Bernard M Fine
@en
Bernard M Fine
@es
Bernard M Fine
@nl
type
label
Bernard M Fine
@ast
Bernard M Fine
@en
Bernard M Fine
@es
Bernard M Fine
@nl
prefLabel
Bernard M Fine
@ast
Bernard M Fine
@en
Bernard M Fine
@es
Bernard M Fine
@nl
P106
P1153
7102335275
P31
P496
0000-0002-5483-476X